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Background: A patent foramen ovale (PFO) is not widely recognized as a factor
contributing to hypoxemia in patients with chronic obstructive pulmonary disease
(COPD). We therefore sought to clarify the prevalence and clinical significance of a
PFO in patients with COPD, and to analyze the factors related to its occurrence.
Methods: This study included 52 consecutive stable patients with COPD and 50
healthy controls. The demographic and clinical features of the study group were
noted. To test for a PFO, standard and contrast transthoracic echocardiographic
examinations were performed while resting and during the Valsalva maneuver (VM).
Patients performed 6-min walking tests (6 MWT), and the distances traveled were
measured.
Results: During VM, we detected a PFO in 23 COPD patients and 10 healthy controls
(Po0:01). A PFO was detected while resting in 11 COPD patients, but in none of the
controls (P ¼ 0:001). Comparison of multiple parameters between COPD patients
with and without a PFO during VM did not reveal any clinically significant
differences. When we compared COPD patients with and without a PFO during
resting, however, we found that the former had longer durations of disease, lower
PaO2 and SaO2, higher dyspnea scores, shorter distances walked during 6 MWT and
higher desaturation rates (Po0:05). Logistic regression analysis showed that longer
duration of disease, lower SaO2 and higher systolic pulmonary artery pressure were
independent predictors of the occurrence of a PFO in resting COPD patients.Elsevier Ltd. All rights reserved.
3410660x3807; fax: +90 422 3410728.
nu.edu.tr (S.S. Hacievliyagil).
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S.S. Hacievliyagil et al.904Conclusions: The prevalence of a PFO is higher in patients with COPD than in
healthy individuals. The presence of a PFO while resting may contribute significantly
to the deterioration of arterial oxygenation and performance status. These findings
indicate that a PFO may be a principle cause of hypoxemia in patients with COPD.
& 2005 Elsevier Ltd. All rights reserved.Introduction
A patent foramen ovale (PFO) is detected in about
10–35% of normal individuals.1–6 In most people,
functional closure of the foramen ovale occurs just
after birth, when the pulmonary vascular pressure
decreases with spontaneous breathing movements,
and left atrial pressure exceeds right atrial pres-
sure. However, this functional sealing may not be
complete in all individuals, and right to left
shunting continues to occur during strenuous
activities such as singing, yelling, coughing, strain-
ing for bowel movements, and performing spiro-
metry. Clinically important consequences of this
right to left shunting through a PFO may include
cerebrovascular events due to paradoxical embo-
lism7,8 and severe arterial hemoglobin-oxygen
desaturation in hemodynamically unstable pa-
tients.1,6,9 However, the clinical significance of
such transient shunting episodes remains contro-
versial because they are of very short duration and
their frequency is too low to generate clinical
problems in most individuals.
In exceptional situations, the right to left
shunting may become continuous, generating phy-
siologic consequences. Individuals with persistent
primary or secondary pulmonary hypertension are
at increased risk of shunting; however, to date only
one published study has directly addressed the
prevalence of a PFO in this population.6 In that
study, which was carried out in a relatively small
group of patients (n ¼ 58), the prevalence rates of
PFO in patients with primary and secondary
pulmonary hypertension were found to be 25% and
28%, respectively. Chronic obstructive pulmonary
disease (COPD) is one of the main causes of
secondary pulmonary hypertension. During the
advanced stage of COPD, alveolar hypoventilation
frequently leads to pulmonary hypertension of
varying degrees. However, only a few studies have
examined the prevalence and clinical significance
of a PFO in patients with COPD. In the studies
performed to date, the Valsalva maneuver (VM) has
been utilized as the standard procedure for the
detection of a PFO. Using this procedure, Soliman
et al. found the prevalence of a PFO to be higher in
COPD patients than in normal subjects (70% versus
35%).9 However, clinicians have not been able to
determine the significance of a PFO in these patientpopulations, making it difficult to determine the
clinical importance of its treatment.
We therefore sought to clarify the pre-
valence and clinical significance of a PFO in
patients with stable COPD. We measured the
effect of a PFO on arterial oxygenation and
analyzed the correlation of several clinical para-
meters with the presence of a PFO. In addition to
determining the incidence of a PFO in response to
VM, we also measured the incidence of a PFO in
patients during normal breathing and exercise
testing.Patients and methods
The study was performed at the Turgut Ozal
Research Center of Inonu University, Malatya,
Turkey. The study protocol was approved by the
ethics committee of the center, and informed
written consent was obtained from all subjects
prior to entry into the study. We prospectively
enrolled 74 consecutive patients with stable COPD
who had been admitted to our center’s outpatient
clinics for their scheduled visits for COPD, most on
a 3–6 month basis. Diagnosis of COPD was made
according to the criteria set by the American
Thoracic Society (ATS).10 Patients were excluded
from the study if they had had an acute attack
within 1 month prior to enrollment, or if they had
been diagnosed with primary or secondary cardiac
disorders not related to COPD that could affect
arterial oxygenation or cause right to left shunting.
Subjects not enrolled or excluded after enrollment
included those with hypoventilation syndromes
(obstructive sleep apnea syndrome, or obesity-
hypoventilation syndrome or primary hypoventila-
tion) or primary or secondary cardiac or pulmonary
diseases, based on their medical histories, past
medical records and results of a detailed physical
examination.
As a control group, we enrolled 50 healthy
subjects over 40 years of age. These control
subjects were recruited from patients admitted to
the outpatient clinics of the cardiology department
of our center due to suspicious cardiological
symptoms, but who were diagnosed as normal after
detailed examination.
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patients, including age, disease duration, and
smoking load (pack-years). Clinical examinations
included detailed hemograms, and biochemical,
spirometric and arterial blood gas analysis. Disease
duration was measured from the date of first visit
to a doctor for chronic cough, dyspnea or sputum
production. This information was obtained by
reviewing personal and official medical documents
and by asking the patients multiple cross questions.
Severity of dyspnea was assessed according to the
Modified Medical Research Council (MMRC) scale,
which ranged from 0 (not being troubled by
shortness of breath except with strenuous exercise)
to 5 (being too breathless to leave the house or
breathless when dressing or undressing).11Study protocol(1) After noting age and disease duration, we took
standard PA chest films for all patients and
controls. Patients with results that were not
normal for COPD, including those with hyperin-
flation, increased radiolucency, diaphragmatic
flattening, and increased diameter of pulmon-
ary arteries, were excluded from the study.(2) A spirometric examination was performed on all
patients, according to standard ATS proce-
dures,12 using a Vmax 20c spirometer (Sensor-
Medics Corp., Yorba Linda, CA, USA).(3) Arterial blood gas analysis was performed in all
patients while they were breathing room air at
rest.(4) All patients and controls underwent detailed
transthoracic color flow and pulsed Doppler
echocardiographic examination, with and with-
out injection of agitated physiologic saline as
contrast material. The same cardiologist per-
formed all the transthoracic echocardiography
(TTE) examinations, and all measurements
were performed using the same machine and
its related equipment (ATLHDI 5000 CV, Mecha-
tronics, Seattle, WA, USA). The peak velocity of
tricuspid regurgitant flow was recorded, and
the systolic pulmonary artery pressure (PAPS)
was measured using the modified Bernoulli
equation, as described previously.13 The con-
trast echocardiograpic examination was per-
formed to assess flow patterns across the
foramen ovale. Boluses of agitated physiologic
saline were rapidly infused into the right
antecubital vein, until the images of these
echogenic microbubbles were clearly visualized
in the right atrium. A PFO was deemed to be
present if the microbubbles clearly traversedthe interatrial septum from right to left, or if
six or more microbubbles were detected in the
left atrium within three cardiac cycles after
total opacification of the right atrium. This
procedure was repeated several times, both
during normal breathing and VM. Interatrial
septal defects were differentiated by both
color and spectral Doppler. Only data from
patients with good to excellent echocardio-
graphic images were assessed further. These
patients were monitored by finger pulse oxy-
metry during echocardiography, and changes in
hemoglobin oxygen saturation during VM were
noted. The echocardiographic technique used
and its reliability are described in detail else-
where.14,15(5) A standard 6-min walking test (6 MWT) in a 50m
long corridor was performed in all patients, and
the distance walked by each patient was
measured.Statistical analysis
All variables were reported as mean7SD. The w2
test was used to compare differences in PFO
prevalence between patients with COPD and
normal controls. These differences were calculated
during both normal breathing and VM. The patients
with COPD were subsequently divided into three
groups: those without a PFO (Group I), those with a
PFO only during VM (Group II), and those with a PFO
during normal breathing (Group III). Demographic
and clinical data obtained from spirometric exam-
ination, echocardiographic evaluation and 6 MWT
were compared among these three groups. Subse-
quently, Groups I and II were combined and
compared with Group III, and Groups II and III were
combined and compared with Group I. To deter-
mine the independent parameters predicting a
PFO, we used the Mann–Whitney U test. Sensitivity
and specificity analysis for predicting a PFO was
performed for all statistically significant para-
meters using the ROC curve method.
To better analyze the relationship between
multiple variables and the occurrence of a PFO,
we used the logistic regression method, with the
presence or absence of a PFO as the dependent
variable. Two types of model were used for this
analysis. In the first, we analyzed the effect of
independent variables on the occurrence of all PFO
cases (29 patients in Group I versus 23 in Groups II
plus III). In the second model, we analyzed the
effect of independent variables on the occurrence
of a PFO during normal breathing (41 patients in
Groups I plus II versus 11 in Group III). Both models
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duration of the disease, cigarette load, PaO2,
SaO2, FEV1 and PAPS). A P-value of less than 0.05
was considered statistically significant.Results
Of the starting cohort of 74 patients, 52 (47 males,
5 females) completed the study. The data from the
other 22 patients were not assessed further due to
poor echogenicity during TTE. No patients or
control subjects were removed from the study on
the basis of results of PA chest films and spirometric
measurements. In the control group, the TTE
findings were evaluated as normal. Table 1 lists
the general characteristics of the patients with
COPD.
A PFO was detected in 23 COPD patients (44%)
and 10 controls (20%) during VM (P ¼ 0:009). Of the
former, 11 patients also had a PFO during normal
breathing, compared with none of the control
subjects (P ¼ 0:001). Table 2 lists the general
characteristics and the comparison results of the
patients in Groups I–III. No significant differences
were observed between Groups I and II with respect
to the relevant parameters, except for desatura-
tion rate during VM (P ¼ 0:001). Differences be-
tween Groups I and III were statistically significant
for parameters such as disease duration (P ¼Table 1 The general characteristics of the
patients.
Characteristics Total
(n ¼ 52)
Age (year) 65.678.8
Disease duration (year) 11.677.1
Cigarette load (pack-years) 46.3728.9
pH 7.4670.04
PaO2 (mmHg) 59.8711.8
PaCO2 (mmHg) 43.579.6
SaO2 (%) 89.976.4
FVC (%predicted) 72.7720.2
FEV1 (%predicted) 44.7713.4
FEV1/FVC 49.8713.5
MMRC dyspnea scale 2.9470.94
Hematocrit (%) 47.676.5
Albumin (g/dL) 3.670.5
BMI (kg/m2) 22.873.9
PAPS (mmHg) 51.4718.9
6 MWT (m) 3547154
Desaturation rates during
valsalva maneuver
0.9471.35
MMRC: Modified Medical Research Council.0:007), PaO2 (P ¼ 0:006), SaO2 (P ¼ 0:002), MMRC
scale (P ¼ 0:043), PAPS (P ¼ 0:008), distance tra-
veled during 6MWT (p ¼ 0:012) and desaturation
rate during VM (Po0:001). Differences between
Groups II and III were statistically significant for
parameters such as disease duration (P ¼ 0:036),
SaO2 (P ¼ 0:012), MMRC scale (P ¼ 0:005), distance
traveled during 6 MWT (P ¼ 0:028), and desatura-
tion rate during VM (P ¼ 0:001).
When we compared Group I with the rest of the
patients, we observed significant differences in the
variances of PaO2 (P ¼ 0:016) and SaO2 (P ¼ 0:041),
and in the desaturation rate during VM (Po0:001)
(Table 3). Similarly, when we compared Group III
with the rest of the patients, we observed
statistically significant differences in disease
duration (P ¼ 0:006), PaO2 (P ¼ 0:012), SaO2
(P ¼ 0:001), MMRC scale (P ¼ 0:015), PAPS (P ¼
0:01), distance traveled during 6 MWT (P ¼ 0:008)
and desaturation rate during VM (Po0:001). Lower
resting hemoglobin-oxygen saturation, except for
the comparison between Groups I and II, and higher
desaturation rates during VM revealed statistically
significant results in all comparisons. None of these
statistically significant parameters, however,
yielded clinically important sensitivity and specifi-
city values that would predict a PFO on the ROC
curve method.
When we used logistic regression analysis to
determine the important factors associated with
the occurrence of a PFO, both during normal
breathing and VM, we found that age, duration of
disease, cigarette load, PaO2, SaO2, FEV1 and PAPS
did not show a significant association with occur-
rence of a PFO (Table 4). According to this model,
the negative predictive power was 82.8% and the
positive predictive power was 69.6%, whereas the
overall predictive power was 76.9%. Using the same
method of analysis to determine the factors
associated with the occurrence of a PFO only
during normal breathing (n ¼ 11) showed that this
condition was associated with disease duration
(P ¼ 0:032), SaO2 (P ¼ 0:034) and PAPS (P ¼ 0:034)
(Table 5). Thus, the negative predictive power of
this model was 95.1% and the positive predictive
power was 72.7%, whereas the overall predictive
power was 90.4%.Discussion
In this study, we sought to determine the pre-
valence and clinical significance of a PFO in
patients with COPD. Our results strongly support
previous findings that the prevalence of a PFO
ARTICLE IN PRESS
Table 2 The comparison of the patients in Groups I–III.
Characteristics COPD patients
without PFO
(Group I) (n ¼ 29)
COPD patients with
PFO only during
valsalva maneuver
(Group II) (n ¼ 12)
COPD patients with
PFO during resting
(Group III) (n ¼ 11)
Age (year) 65.678.5 65.3710.2 66.179.0
Disease duration (year) 10.375.9# 11.2710.0* 15.475.4*,#
Cigarette load (pack-years) 44.8729.8 51.4729.2 44.7728.6
pH 7.4670.05 7.4670.04 7.4570.05
PaO2 (mmHg) 63.3711.5
# 59.2711.7 51.178.6#
PaCO2 (mmHg) 43.9710.2 40.476.9 45.9710.5
SaO2 (%) 91.775.6
# 91.176.1# 84.176.0#,#
FVC (%predicted) 70.4721.3 78.3718.7 72.7719.2
FEV1 (%predicted) 45.5714.8 46.3713.9 41.078.9
FEV1/FVC 52.5715.0 46.379.9 46.5712.0
MMRC dyspnea scale 2.8670.99* 2.5870.79# 3.5570.68*,#
Hematocrit (%) 46.777.2 48.775.9 49.175.4
Albumin (g/dL) 3.670.4 3.670.5 3.670.9
BMI (kg/m2) 22.473.5 24.374.8 21.973.7
PAPS (mmHg) 46.6713.8
# 51.5718.9 64.2725.5#
6 MWT (m) 3867156# 3787139* 2467127#,*
Desaturation rates during valsalva
maneuver
0.1470.52#,b 1.171.0#,# 2.9171.14b,#
COPD: Chronic Obstructive Pulmonary Disease.
PFO: Patent Foramen Ovale.
MMRC: Modified Medical Research Council.
*0.01pPo0.05; #0.001pPo0.01; bPo0.001.
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than in normal subjects. In contrast to previous
findings, however, we observed that about 20% of
COPD patients with a PFO suffer from right to left
shunting even at rest, and the negative impact of
this condition on exercise capacity is clinically
significant in this subgroup. The occurrence of a
PFO while resting was related to disease duration,
arterial oxygen content, and PAPS. In contrast, we
found no correlation between the presence of a
PFO only during VM and any of the demographic and
clinical parameters, indicating that the presence a
PFO solely during VM does not have clinical
significance.
Hypoxemia in COPD is related to multiple factors,
among the most important of which are distur-
bances in ventilation–perfusion ratio, decreased
diffusing capacity, increased dead space, and
respiratory muscle fatigue.16 Other factors include
deterioration of performance status, increased
closing volume, fibrosis, loss of alveolar capillary
bed and genetic variations in the ventilatory
drive.16 It is well known that hypoxemia in patients
with COPD is due to a combination of factors rather
than a single factor. A clinically important hypoxe-
mic state (PaO2p60mmHg) has been found todevelop during the advanced stages of COPD, and
in COPD patients with FEV1 less than 50% of the
predicted value.16,17 Right to left shunting through
the foramen ovale is not recognized as contributing
to hypoxemia in COPD. Although the prevalence of
a PFO during VM has been reported for a group of
patients with severe COPD, that study did not
determine right to left shunting during resting, nor
did it address the clinical importance of a PFO.9
The foramen ovale permits the passage of blood
from right to left in some normal individuals, and
the same should be true for patients with COPD.
Although the clinical impact of this shunting is
negligible in normal individuals, this is probably not
the case in all COPD patients. Our results suggest
that assessing individuals for the presence of a PFO
only during strenuous effort gives misleading
information, and does not completely reflect its
clinical effects. The most important subgroup of
patients in whom a PFO has some clinical signifi-
cance is those who are shunt positive both during
VM and while resting. The assessment of MMRC
scales and response to 6 MWT in COPD patients
exhibiting shunting only during VM was similar to
that of COPD patients without shunting. The
desaturation rate during VM was found to be higher
ARTICLE IN PRESS
Table 4 The results of logistic regression analysis for the relationship of all PFO cases with independent
variables.
Variables B Exp (B) %95 CI P
Age (year) 0.006 0.994 0.914–1.080 0.881
Disease duration (year) 0.050 1.045 0.956–1.142 0.332
Cigarette smoking (pack-years) 0.009 1.010 0.986–1.034 0.434
PaO2 (mmHg) 0.035 0.965 0.893–1.044 0.380
SaO2 (%) 0.052 0.949 0.832–1.082 0.435
FEV1 (%predicted) 0.011 0.989 0.938–1.043 0.685
PAPs (mmHg) 0.038 1.039 0.993–1.087 0.101
Constant 4.501
PFO: Patent Foramen Ovale.
Table 3 The comparison analysis of different combinations of the patients in Group I–III.
Characteristics COPD patients
without PFO
(Group I)
(n ¼ 29)
All patients
with PFO
(Group II and
Group III)
(n ¼ 23)
COPD patients
without
PFO and with PFO
only
during Valsalva
maneuver
(Groups I and II)
(n ¼ 41)
COPD patients
with PFO during
resting
(Group III)
(n ¼ 11)
Age (year) 65.678.5 65.779.4 65.578.9 66.179.0
Disease duration (year) 10.375.9 13.278.2 10.677.2 15.475.4#
Cigarette smoking
(pack-years)
44.8729.8 48.2728.5 46.7729.4 44.7728.6
pH 7.4670.05 7.4670.04 7.4670.04 7.4570.05
PaO2 (mmHg) 63.3711.5 55.3710.9* 62.1711.6 51.178.6
#
PaCO2 (mmHg) 43.9710.2 43.079.0 42.979.4 45.9710.5
SaO2 (%) 91.775.6 87.776.9* 91.575.7 84.176.0
#
FVC (%predicted) 70.4721.3 75.7718.7 72.7720.7 72.7719.2
FEV1 (%predicted) 45.5714.8 43.7711.8 45.7714.3 41.078.9
FEV1/FVC 52.5715.0 46.4710.7 50.7713.9 46.5712.0
MMRC dyspnea scale 2.8670.99 3.0470.88 2.7870.93 3.5570.68*
Hematocrit (%) 46.777.2 48.975.5 47.376.8 49.175.4
Albumin (g/dL) 3.670.4 3.670.7 3.670.4 3.670.9
BMI (kg/m2) 22.473.5 23.174.3 23.073.9 21.973.7
PAPS (mmHg) 46.6713.8 57.6722.7 48.0715.4 64.2725.5
#
6 MWT (meters) 3867156 3157147 3847149 2467127#
Desaturation rates
during valsalva
maneuver
0.1470.52 1.9671.4b 0.4170.81 2.9171.14b
COPD: Chronic Obstructive Pulmonary Disease.
PFO: Patent Foramen Ovale.
MMRC: Modified Medical Research Council.
* 0.01pPo0.05; #0.001pPo0.01; bPo0.001
S.S. Hacievliyagil et al.908in the former group (Group II). However, since the
difference between the mean desaturation rates of
Groups I and II was less than 1%, this difference was
evaluated as an expected physiologic finding of no
consequence.
Longer duration of disease showed the highest
statistical significance among the factors that couldinfluence the occurrence of a PFO at rest. This is
reasonable, because exposure to alveolar hypoven-
tilation for longer periods of time may lead to
higher pulmonary artery pressures, resulting in
permanent functional opening of the foramen
ovale. COPD patients with a PFO both during VM
and while at rest had higher MMRC scales, higher
ARTICLE IN PRESS
Table 5 The results of logistic regression analysis for the relationship of PFO cases during resting with
independent variables.
Variables B Exp (B) %95 CI P
Age (year) 0.120 1.127 0.906–1.402 0.284
Disease duration (year) 0.186 1.205 1.016–1.428 0.032
Cigarette smoking (pack-years) 0.039 1.040 0.995–1.087 0.085
PaO2 (mmHg) 0.024 0.976 0.862–1.106 0.709
SaO2 (%) 0.484 0.616 0.391–0.971 0.034
FEV1 (%predicted) 0.228 0.796 0.598–1.059 0.118
PAPS (mmHg) 0.114 1.121 1.009–1.245 0.034
Constant 33.085
PFO: Patent Foramen Ovale.
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distances during 6 MWT, when compared with
patients with a PFO only during VM. Similar results
were obtained when COPD patients with a PFO both
during VM and while at rest were compared with
COPD patients without a PFO under all conditions.
When we combined Groups I and II, we found that
the average desaturation rate in this combined
group was 2.5% less than that in Group III. Similarly,
the average MMRC scale was 0.77 point lower for
the combined group than for Group III. The 6 MWT is
a standard method for measuring the performance
status of patients with COPD and for monitoring the
progression of the disease.18,19 In addition, the 6
MWT results of COPD patients correlate well with
disease severity. Although the mean age and the
staging of the disease according to FEV1 did not
differ between the Group III patients and the other
patients, the former walked 140 and 132m less
than the patients in Groups I and II, respectively.
This was important, because the similarity of these
2 key parameters (mean age and the staging of the
disease) in all groups made the results of the
comparisons more powerful and the differences
more meaningful. The results obtained by compar-
ing Group III with all other patients (Groups I and II
combined) were the same as for the comparisons
between Group III and Groups I and II individually.
To our knowledge, this study is first to show that
a PFO has clinical significance in COPD patients, as
well as being the first to show differences between
having a PFO at rest and having a PFO only during
VM. In particular, the present results indicate that a
PFO has clinically important consequences in 20% of
patients with COPD, with regard to arterial oxygen
content and performance status.
The models we developed to determine the
relationship between multiple independent vari-
ables and either all PFO cases (Groups II and III) or
only those with a PFO at rest (Group III) gave goodoverall predictive power (76.9% and 90.4%, respec-
tively). It is clear that the superior overall
predictive power of the second model is more
important clinically. We also found that the
negative predictive powers of both models were
stronger than the positive predictive values. None
of the variables included in the first model,
however, reached statistical significance. This was
likely a consequence of combining Groups II and III.
Specifically, the results of Group II were similar to
those of Group I, and hence mixing the Group II and
III data may have interfered with the model. In
previous studies, patients were tested for a PFO
only during VM. This may be why previous investi-
gators reported no clinical impact of a PFO. In the
second model, we combined Groups I and II, which
appeared to overcome the deficiencies of the first
model. The second model revealed several factors
related to the occurrence of a PFO, including
disease duration, SaO2 and PAPS.
A PFO has been suggested to protect patients
with pulmonary hypertension against further eleva-
tion of pulmonary artery pressure and against
further deterioration of cardiac function.20 How-
ever, this finding could not be confirmed, and no
difference in survival was observed between
patients with and without pulmonary hyperten-
sion.9,21,22 A PFO may contribute to the deteriora-
tion of arterial oxygen content by further
increasing pulmonary artery pressure, which will
increase the right to left shunting of deoxygenated
blood. As a result of this vicious circle, the
progression of the disease will be accelerated. We
found that PAPS was significantly different between
Groups I and III, and between Groups I plus II and
Group III. Although the mean PAPS values were
similar in Groups II and III, exercise capacity was
significantly lower in Group III. This condition
suggests a limited role of pulmonary artery pres-
sure in reducing exercise capacity. Regardless of
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desaturation rate was significantly higher during VM
in COPD patients with a permanent PFO (Group III).
This may be regarded as direct evidence for the
negative contribution of a PFO to pulmonary
mechanics and exercise capacity. These findings,
however, do not necessarily mean that increased
pulmonary artery pressure has no influence on the
permanent patency of the foramen ovale, but
rather that the relationship is somewhat nonlinear.
One possible criticism of our study is that we
used TTE rather than transesophageal echocardio-
graphy (TEE), the method favored by most inves-
tigators due to its better echogenicity. However,
the new generation of echocardiography machines
and their related equipment has much better
resolution and echogenicity than older machines.
A meta-analysis revealed only a slight difference
between TTE and TEE in regard to their ability to
detect a PFO (9.3% versus 11.2%, respectively).23 In
addition, we only included patients with good to
excellent echogenicity on TTE in our study, exclud-
ing data from 22 patients with unsatisfactory
images. Thus, we do not believe that our use of
TTE had any significant influence on our results.
In conclusion, we have shown here that a PFO, if
present during resting, may contribute significantly
to arterial deoxygenation and has a negative effect
on performance status of patients with COPD. Our
findings indicate that detection of a PFO only
during strenuous exercise may be insufficient to
identify truly affected patients, and that a PFO
should also be demonstrated during resting periods.
Our results suggest that a PFO may be one of the
main factors contributing to hypoxemia in patients
with COPD, and that hypoxemic patients should be
tested for it.References
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